Literature DB >> 22859214

Photopheresis (extracorporeal photochemotherapy).

Franz Trautinger1, Ulrike Just, Robert Knobler.   

Abstract

Photopheresis is a form of phototherapy where specialized equipment is used to isolate a leukocyte fraction from the peripheral blood which is then exposed to photoactivated 8-methoxypsoralen and reinfused into the patient. At the time of its invention the treatment was conceptually based on the hypothesis of T cell vaccination, i.e. the observation in experimental studies that exposure of the immune system to physically modified T cell clones leads to a specific inhibition of T cell mediated autoimmunity. Consequently, photopheresis has been tried in a variety of conditions where T cells are thought to have a critical role and has shown clinical efficacy mainly in variants of cutaneous T cell lymphomas, graft-versus-host disease, systemic sclerosis, in solid organ transplant rejection and Crohn's disease. Evidence has accumulated that alterations in antigen presentation and the generation of regulatory T cells are induced by photopheresis and might be related to the observed clinical effects. Summarizing what has been published in the 25 years since its introduction into the clinic, photopheresis to date has found its place in the treatment of the above mentioned conditions as a well tolerated treatment option that can safely be combined with other established modalities. It can be expected that further research will help refine its clinical indications and close the gaps that still exist in our knowledge on when, how, and why photopheresis works.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22859214     DOI: 10.1039/c2pp25144b

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  6 in total

1.  4,6,4'-trimethylangelicin shows high anti-proliferative activity on DU145 cells under both UVA and blue light.

Authors:  G Miolo; G Sturaro; G Cigolini; L Menilli; A Tasso; I Zago; M T Conconi
Journal:  Cell Prolif       Date:  2018-01-10       Impact factor: 6.831

2.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

3.  Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities.

Authors:  Uffe Koppelhus; Johan Poulsen; Niels Grunnet; Mette Søndergaard Deleuran; Erik Obitz
Journal:  Front Med (Lausanne)       Date:  2014-10-01

Review 4.  Extracorporeal Photopheresis: Tolerogenic or Immunogenic Cell Death? Beyond Current Dogma.

Authors:  Dalil Hannani
Journal:  Front Immunol       Date:  2015-07-07       Impact factor: 7.561

5.  Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions.

Authors:  Sara Castiglia; Katia Mareschi; Luciana Labanca; Graziella Lucania; Marco Leone; Fiorella Sanavio; Laura Castello; Deborah Rustichelli; Elena Signorino; Monica Gunetti; Massimiliano Bergallo; Anna Maria Bordiga; Ivana Ferrero; Franca Fagioli
Journal:  Cytotherapy       Date:  2014-02-12       Impact factor: 5.414

6.  European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-06       Impact factor: 6.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.